CAR-T Cell Therapy for Relapsed or Resistant Acute Lymphoblastic Leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This study follows patients receiving CAR-T cell therapy—an advanced treatment where immune cells are modified to fight leukemia—for acute lymphoblastic leukemia (ALL) that has returned or didn't respond to initial treatment. The trial tracks how well the therapy works and its safety in both children and adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute lymphoblastic leukemia (ALL) that is CD19-positive
- Your ALL has either returned after treatment or did not respond to initial therapy
- You are any age (pediatric patients under 18 or adults 18 and older)
- Your doctor has prescribed one of the approved CAR-T cell therapies: tisagenlecleucel, brexucabtagene autoleucel, or obecabtagene autoleucel
- You are willing to allow your medical data to be collected and used for this study, as permitted by local laws
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
This trial tests a new treatment using the patient's own immune cells, modified to find and attack leukemia cells that remain after initial chemotherapy. It's for children with B-cell acute lymphoblastic leukemia who still have tiny amounts of cancer cells detectable after standard treatment.
This trial tests a new CAR-T cell therapy (FIT-CD19-CAR-T) for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The goal is to see if this treatment is safe and can help control the leukemia.
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
This trial tests a new immunotherapy using your own immune cells (CAR T-cells) that are modified to find and kill cancer cells that have a protein called CD19 or CD22. It is for adults whose acute lymphoblastic leukemia (ALL) or lymphoma has come back or did not respond to previous treatments.
This trial tests whether specially designed immune cells (CAR T cells) that target CD19 can help adults whose B-cell acute lymphoblastic leukemia has not responded to standard treatments or has returned. The cells are made from your own blood and given back to you after a short chemotherapy preparation.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.